Bayer's $400M Cipro Payout Strangled Market, Consumers Say

Law360, New York (April 02, 2012, 2:55 PM ET) -- A class of consumers argued before California's highest court last week that Bayer AG's $400 million pay-for-delay patent settlement preventing Barr Pharmaceuticals Inc. from selling its generic version of the antibiotic Cipro preserved a monopoly for Bayer that allowed the company to rake in profits.

In their opening brief before the California Supreme Court on March 27, indirect Cipro purchasers asked the court to reverse the state Court of Appeal's ruling last year holding that Bayer's pay-for-delay settlements with Barr hadn't broken competition laws, saying the...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required